Prevalence of bisphosphonate-related osteonecrosis in patients with cancer could be as high as 13.3 percent.
SYSTEMATIC REVIEW CONCLUSION: The overall mean weighted prevalence of bisphosphonate-related osteonecrosis (BON) in the evaluated studies was 6.1 percent, and the overall weighted prevalence of BON in studies with documented follow-up was 13.3 percent. CRITICAL SUMMARY ASSESSMENT: There is inconsistency in prevalence study results and a lack of studies in which investigators have evaluated quality-of-life issues related to or the economic effects of BON in patients with cancer.